---

April 14 2008 Amarillo Biosciences Appoints Dr. Peter Mueller Chief Operating Officer and Director of Research. March 25 2008 Amarillo Biosciences Enters Into a License and Supply Agreement with CytoPharm for Low Dose Oral Interferon Use in Animal Diseases in China and Taiwan. CytoPharm to Conduct Animal Clinical Trials and Seek Regulatory Approval for Amarillo Biosciences’ Low Dose Oral Interferon. March 3 2008 Amarillo Biosciences Oral Warts Study Enrollment at Halfway Point. The Patient Recruiting Agency Retained to Accelerate Enrollment. February 19 2008 Amarillo Bioscience Partner CytoPharm to Conduct 144 Patient Phase 2 Hepatitis C Trial in Taiwan. January 16 2008 Amarillo Biosciences Appoints Kimball Miller, MD as Medical Director. January 14 2008 Texas Tech University to Create the West Texas Influenza Research Center — Center Funded by a U.S. Federal Government Grant. January 10 2008 Amarillo Biosciences Announces Private Placement by Firebird Global Master Fund. December 4 2007 Amarillo Biosciences Files Patent Application to Treat Chronic Cough with Oral Interferon. October 9 2007 Amarillo Biosciences Issues Clinical Trials Update. August 24 2007 Amarillo Biosciences Recaps Progress in 2007. August 2 2007 Amarillo Biosciences Plans a Human Influenza Clinical Trial in Perth, Australia.